The PLEKHG6 antibody targets the protein encoded by the PLEKHG6 gene (also known as ARHGEF36), a member of the Rho guanine nucleotide exchange factor (RhoGEF) family. RhoGEFs regulate Rho GTPases, which are critical for cytoskeletal reorganization, cell migration, and signaling. PLEKHG6 contains a pleckstrin homology (PH) domain and a Dbl homology (DH) domain, enabling interactions with GTPases like RAC1 to modulate downstream pathways, including PI3K/AKT and MAPK signaling. Research suggests PLEKHG6 is involved in neural development, cancer progression, and immune responses.
Antibodies against PLEKHG6 are essential tools for studying its expression, localization, and function. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate PLEKHG6's role in diseases. For instance, studies indicate PLEKHG6 overexpression in glioblastoma, breast cancer, and melanoma, where it may promote tumor invasion and metastasis. Its potential as a therapeutic target or biomarker has spurred interest in developing specific antibodies for diagnostic and functional studies.
Commercial PLEKHG6 antibodies vary in host species, clonality, and conjugation, with validation data critical for ensuring specificity. Recent work also explores PLEKHG6's interaction with neurodevelopmental disorders and its regulatory effects on autophagy. However, challenges remain in fully elucidating its mechanistic contributions across biological contexts.